Gilead Adds To Virology Focus Through 12-Year Collaboration With Assembly

Gilead gets option rights to Assembly’s entire virology pipeline, including future assets, for herpesvirus and hepatitis B and D. The deal provides financial stability and opt-in potential for Assembly.